Soquelitinib [CAS 2226636-04-8]

Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8+ cells that possess enhanced T effector function[1][2][3].

[2226636-04-8]

C25H30N4O4S2

514.66

O=C(N1C[C@H](N(CCC1)C(C=C)=O)C)C2=C(C=C(C(SC3=CN=C(NC(C4CC4)=O)S3)=C2)C)OC

Itk

10mM

99.71

DMSO : ≥ 100 mg/mL

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature